These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 11961039)

  • 1. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
    Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C
    J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit.
    Grundmann S; Hoefer I; Ulusans S; van Royen N; Schirmer SH; Ozaki CK; Bode C; Piek JJ; Buschmann I
    Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1497-505. PubMed ID: 15923311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
    Mitoma H; Horiuchi T; Hatta N; Tsukamoto H; Harashima S; Kikuchi Y; Otsuka J; Okamura S; Fujita S; Harada M
    Gastroenterology; 2005 Feb; 128(2):376-92. PubMed ID: 15685549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
    Agnholt J; Dahlerup JF; Kaltoft K
    Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular differences in anticytokine therapies.
    Calabrese LH
    Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-target activity of TNF-alpha inhibitors characterized by protein biochips.
    Feyen O; Lueking A; Kowald A; Stephan C; Meyer HE; Göbel U; Niehues T
    Anal Bioanal Chem; 2008 Jul; 391(5):1713-20. PubMed ID: 18344017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes.
    Haider AS; Cardinale IR; Whynot JA; Krueger JG
    J Investig Dermatol Symp Proc; 2007 May; 12(1):9-15. PubMed ID: 17502863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms.
    Kim MS; Lee SH; Song MY; Yoo TH; Lee BK; Kim YS
    J Mol Biol; 2007 Dec; 374(5):1374-88. PubMed ID: 17996896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differences in pharmacology of tumor necrosis factor (TNF) antagonists].
    Fiocco U; Bombardieri S
    Reumatismo; 2005; 57(4 Suppl):8-16. PubMed ID: 16385350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.